Introduction
============

Tuberculosis (TB), which has killed more humans than any infectious disease, remains a global health challenge. Over 10 million people got sick and 1.4 million individuals died of TB in 2015, with most of the affected individuals living in resource-constrained countries.[@b1-idr-11-239] The burden of TB is worsened by the emergence of strains that are resistant to standard TB drugs, threatening to make a treatable disease untreatable. Individuals infected with resistant strains have to take anti-TB drugs for longer periods and cure rates are lower compared to infection with susceptible strains.[@b1-idr-11-239],[@b2-idr-11-239]

The standard World Health Organization (WHO)-approved treatment greatly relies on the use of two potent drugs, that is, isoniazid (INH) and rifampicin (RIF).[@b3-idr-11-239],[@b4-idr-11-239] TB strains that are resistant to these two drugs are classified as multidrug-resistant TB (MDR-TB). More severe forms of TB drug resistance are pre-extensively drug-resistant TB (pre-XDR-TB) and extensively drug-resistant TB (XDR-TB).[@b1-idr-11-239],[@b5-idr-11-239]--[@b9-idr-11-239] XDR-TB has been reported in 117 countries worldwide with treatment success of 28%.[@b1-idr-11-239]

The first key intervention for controlling drug resistance is early detection, for appropriate treatment.[@b1-idr-11-239],[@b2-idr-11-239] The increased use of new and rapid diagnostic tools such as Xpert MTB/RIF and line probe assays (GenoType MTB-DRplus and GenoType MTBDRsl) is ensuring that significantly more TB patients are correctly diagnosed on time.

The National Tuberculosis Control Programme (NTP), Ghana, is now rolling out some of these rapid diagnostic methods to support case management: GenoType MTB-DRplus for rapid detection of MDR-TB, which has been evaluated for use in Ghana,[@b10-idr-11-239] Xpert MTB/RIF for RIF resistance and GenoType MTBDRsl for detection of XDR-TB.

There is limited data on drug resistance in Ghana, especially, resistance to second-line anti-TB drugs. The study objective was to determine the prevalence of second-line anti-TB drug resistance in Ghana.

Materials and methods
=====================

Ethics statement
----------------

The procedure for sample collection, diagnosis and treatment was done in accordance with NTP guidelines,[@b11-idr-11-239] and ethical clearance for this study was obtained from the Noguchi Memorial Institute for Medical Research Institutional Review Board (FWA 00001824, IRB 00001276).

Mycobacterial isolates
----------------------

Isolates analyzed in this study were obtained from pulmonary patients attending various health facilities in the Accra Metro and the East Mamprusi District in the Greater-Accra and Northern regions of Ghana, respectively. The isolates included new TB cases, which form part of a prospective molecular epidemiology study, and those obtained from difficult-to-treat cases attending the Department of Chest Diseases, Korle-Bu Teaching Hospital. The drug susceptibility pattern of the isolates to the first-line anti-TB drugs was determined using the proportion method and GenoType MTBDRplus. In total, 71 (60.7%) MDR-TB, 33 (28.2%) INH monoresistant TB and 13 (11.1%) RIF monoresistant TB isolates were analyzed.

Isolation of genomic DNA
------------------------

A loop full of mycobacterial isolate growing at the log phase was suspended in sterile distilled water and inactivated by heat killing at 95°C for 1 h. Genomic DNA was then extracted using the cetyl-trimethyl-ammonium bromide (CTAB) extraction method developed by Doyle and Doyle with modifications by Käser et al.[@b12-idr-11-239],[@b13-idr-11-239] Briefly, the initial cell lysis was done by resuspending the pellets in lysis buffer containing lysozyme and then incubating overnight at 37°C. Then, 20% sodium dodecyl sulphate (SDS) and 20 mg/mL proteinase K (PK) were added, respectively and mixed gently. The cell debris was removed by adding sodium chloride (NaCl) and prewarmed using CTAB and incubated at 65°C. After incubation with chloroform-isoamyl alcohol at a 24:1 ratio to remove protein debris, the DNA in the aqueous phase was purified with ice-cold isopropanol. The DNA was dried and resuspended in 1X Tris-EDTA buffer.[@b12-idr-11-239],[@b13-idr-11-239]

Anti-TB drug susceptibility testing
-----------------------------------

The Etest (bioMérieux, Marcy-l'Étoil, France) method, which determines the minimum inhibitory concentration (MIC), was used to screen 117 resistant isolates against amikacin (AMK), streptomycin (STR) and moxifloxacin (MOX). McFarland Standard 4 bacteria suspension, corresponding to an approximate cell density of 12.0 ×10^8^ CFU/mL,[@b14-idr-11-239] was prepared using Middlebrook 7H9 with 10% Tween 80 (7H9G-Tween) and inoculated on Middlebrook 7H11 agar plates with oleic albumin dextrose catalase media supplement. Etest strips of distinct drugs were placed aseptically on the plates using forceps and incubated at 37°C.[@b15-idr-11-239],[@b16-idr-11-239] The MIC was determined between 5 and 10 days.[@b17-idr-11-239] The laboratory reference strain, H37Rv, was used as the control for all the assays.

The GenoType MTBDRsl version 2.0 (Hain Lifesciences, Germany), a line probe assay, was used to screen 93 of the 117 phenotypically screened isolates according to the manufacturer's instruction.[@b18-idr-11-239] The isolates used for this assay included all the MDR-TB (71) and RIF monoresistant (13) isolates and an additional nine INH monoresistant isolates.

Mutation analysis of drug targets
---------------------------------

The isolates with high MICs by the Etest method (i.e., ≥2 µg/mL for STR, ≥1 µg/mL for AMK and ≥0.125 µg/mL for MOX) and resistant by the line probe assay were used for targeted DNA sequence analyses. In total, 26 isolates were sequenced including 14 control isolates that were susceptible to all the drugs. DNA segments of the respective resistance conferring genes *gyrA, gyrB, rrs, eis, tlyA, tap* and *whiB7* were amplified using polymerase chain reaction (PCR) for direct DNA sequencing. The PCR for *gyrA, gyrB, tlyA* and *whiB7* contained 5 µL of 10× buffer, 10 µL of Q-solution, 2.5 µL of 15 mM of MgCl~2~, 1 µL of dNTPs, 21.2 µL of nuclease-free water, 2.5 µL each of forward and reverse primers, 0.3 µL of HotStar Taq polymerase and 5 µL of DNA. Cycling conditions were as follows: initial activation step at 95°C for 5 min and 35 cycles of denaturation at 96°C for 1 min, annealing for 1 min at primer-specific temperature Tm ([Table 1](#t1-idr-11-239){ref-type="table"}), extension at 68°C for 1 min and final extension at 72°C for 10 min. The PCR mixtures for *rrs, eis* and *tap* genes contained 25 µL of fast cycling master mix, 10 µL of Q-solution, 2.5 µL of each of the primers, 5 µL of nuclease-free water and 5 µL of DNA template. The cycling conditions included initial denaturation step at 95°C for 5 min and 40 cycles of denaturation at 96°C for 5 s, annealing for 5 s at primer-specific temperature Tm ([Table 1](#t1-idr-11-239){ref-type="table"}), extension at 68°C for 48 s and final extension at 72°C for 1 min.

Data analysis
-------------

Fisher's exact test and chi-squared test were carried out using Stata 14.3 to determine the differences between the patient categories (new TB cases and treatment failure cases) and the frequency of second-line drug-resistant isolates. Also, the correlation coefficient was determined between the year of isolation of the MTB isolates from the patients and the prevalence of anti-TB drug resistance.

Drug resistance according to the line probe assay was indicated by the absence of wild-type band, presence of mutation band, or both. For interpretation of the results, only bands with intensities as strong as or stronger than that of the universal control band were considered.[@b18-idr-11-239]

DNA reads obtained from sequencing were edited and cleaned to remove background noise. The cleaned sequences were screened for mutations by comparing with homologous sequences of *Mycobacterium tuberculosis* strain H37Rv downloaded from the Tuberculist database version 2.6 using the Staden package for DNA analysis.[@b19-idr-11-239],[@b20-idr-11-239] The results from this mutation analysis were compared with the identified mutations from the line probe assay.

Results
=======

Biographical data of study participants
---------------------------------------

Most of the participants were males: 83 (74.8%) males, 28 (25.2%) females and six participants had no record of gender. The average age was 37 years, median age was 34 years and the range was between 13 and 79 years ([Table 2](#t2-idr-11-239){ref-type="table"}). Majority of the participants, 69 (59.0%), were newly diagnosed cases; TB patients with treatment failure were 47 (40.2%) and one relapse case was also included in the study. The residential address of the study participants indicated they were from eight different administrative regions: 72 (61.5%) from Greater Accra region, 21 (17.9%) from Central region, nine (7.7%) from Northern region, seven (6.0%) from Volta region, four (3.4%) from Upper East region and two (1.7%) from Brong/Ahafo region. The participants also included one participant each from Eastern and Western region. The study participants were recruited between 2008 and 2015.

Second-line anti-TB drug profiles
---------------------------------

We determined the MIC values of 117 isolates for STR, AMK and MOX ([Table 3](#t3-idr-11-239){ref-type="table"}). However, one isolate was eliminated from the analysis of the results since it had a result discrepant with another laboratory.

The time for the Etest ellipse to become visible for the MIC determination was recorded for each isolate and 114 (97.4%) of the isolates were read between 5 and 10 days. Out of the total isolates screened, 37 (31.9%) had MICs ≥2 µg/mL for STR and 12 (10.3%) isolates presented with MICs ≥1 µg/mL for AMK. Only one MDR isolate (Isolate ID: TB/Nm 919) had an MIC value ≥0.125 µg/mL for MOX (MIC = 3µg/mL); this isolate also had the highest MIC value for AMK (16 µg/mL) and a very high MIC for STR (32 µg/mL) ([Table 4](#t4-idr-11-239){ref-type="table"}).

Out of 69 isolates from new TB cases, eight (11.59%) were resistant to AMK, while four (8.51%) of the 47 treatment failures were AMK resistant. However, there was no significant difference between these two patient categories (*p* = 0.759). Also, we identified no significant difference between the proportion of isolates resistant to STR among the new TB cases (31.88%) compared to the treatment failures (31.91%, *p* = 0.997). There was only one MOX-resistant isolate which was a treatment failure case. There was no significant difference between the patient categories for MOX resistance (*p* = 0.405).

There was also no correlation between the year of isolation of the MTB isolates from the patients and the prevalence of anti-TB drug resistance (correlation coefficient, *r* = 0).

We screened 93 (including all MDRs) of the 117 isolates by GenoType MTBDRsl version 2.0. As summarized in [Table 3](#t3-idr-11-239){ref-type="table"}, the isolate TB/Nm 919 was cross-resistant to AMK/kanamycin (KAN)/capreomycin (CAP) and also fluoroquinolone resistant. It had a mutation band MT 1, which corresponded to substitution A1401G in the *rrs* gene. Furthermore, there was an absence of a wild-type band (WT 1) in the *gyrA* of this isolate that corresponded to the G88C single-nucleotide polymorphism (SNP), which is associated with resistance to fluoroquinolones. This XDR-TB isolate was cultured from the sputum of a 42-year-old fisherman who had failed TB treatment. He died 2 years after he had reported to the hospital with persistent cough in January 2013. The first drug susceptibility testing conducted showed he was resistant to ethambutol, STR, RIF and INH.

There was no mutation or missing wild-type band in the *eis* and *gyrB* genes among all the isolates screened using the GenoType MTBDRsl version 2.0.

Mutations in aminoglycoside and fluoroquinolone resistance associated target genes
----------------------------------------------------------------------------------

To identify the mutations associated with resistance to fluoroquinolones and aminoglycosides, 26 isolates were tested. Of the 26, 12 were isolates with high MICs for AMK and MOX or resistant by the line probe assay, GenoType MTBDRsl version 2.0. The other 14 were susceptible to all the second-line anti-TB drugs. A non-synonymous mutation, G263T that translates as G88C, was identified in the *gyrA* gene of isolate TB/Nm 919. This same isolate had the SNPs A1401G and A514C in the *rrs* gene ([Table 4](#t4-idr-11-239){ref-type="table"}). We also detected a polymorphism N236K in *tlyA* gene in a drug-susceptible isolate. We did not find any mutation in *gyrB, tap, eis* and *whiB7* genes.

Discussion
==========

This study sought to determine the prevalence of second-line anti-TB drug resistance in Ghana. Prior to this study, only a few drug resistance surveys had been carried out on new TB cases and treatment failure cases in Ghana.[@b17-idr-11-239],[@b21-idr-11-239],[@b22-idr-11-239] The high STR resistance levels observed in this study is even lower than that achieved by Forson et al and Kato et al that recorded 79% and 81%, respectively, among treatment failures in Ghana.[@b22-idr-11-239],[@b23-idr-11-239] The high level of resistance to STR strengthens the WHO's recommendation not to use STR for the treatment of MDR-TB cases.[@b24-idr-11-239] The high prevalence of STR resistance in Ghana can be attributed to its previous use as first-line anti-TB drug and also for treating other ailments and in veterinary medicine.[@b21-idr-11-239],[@b25-idr-11-239],[@b26-idr-11-239]

The first second-line anti-TB drug testing in Ghana by Kato et al was carried out on 5 MDR-TB and 19 monoresistant isolates from four new cases and 17 treated cases. They did not record any resistance to AMK and ofloxacin.[@b22-idr-11-239] However, a later study conducted between 2009 and 2013 in eight West African countries by the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANE-TAM), identified resistance to KAN, CAP and ofloxacin for the first time in Ghana. They also observed a higher prevalence of MDR-TB in new and retreatment cases (6% and 35%, respectively) compared to the WHO estimates of 2% for new cases and 17% for retreatment cases.[@b27-idr-11-239] The study by Kato et al was actually carried out between 2008 and 2009 and the reporting of resistance by the WANETAM indicates the emergence of resistance.[@b22-idr-11-239],[@b27-idr-11-239] The resistance reported by this study also suggests the circulation of resistant strains in the country.

Mutations associated with resistance to fluoroquinolones and aminoglycosides was analyzed by GenoType MTBDRsl version 2.0 and drug target gene sequencing. The G88C mutation observed in the *gyrA* gene by targeted sequencing corresponded with the missing of *gyrA* wild-type band of the GenoType MTBDRsl version 2.0 assay. This mutation has been shown to be associated with resistance to fluoroquinolones.[@b28-idr-11-239],[@b29-idr-11-239] Although a review by Avalos et al observed geographic differences in the *gyrA* mutations across the globe, the use of GenoType MTBDRsl version 2.0 in Ghana was useful in the detection of this resistance-associated mutation.[@b30-idr-11-239]

The target gene sequencing showed three SNPs (A1401G and A514C in *rrs* and N236K in *tlyA*) that are associated with aminoglycoside resistance. The isolate that had *rrs* MUT 1 band of the GenoType MTBDRsl version 2.0 assay also had a corresponding rrs mutation (A1401G). This is a common mutation reported in several studies to be associated with resistance to AMK, KAN and CAP.[@b31-idr-11-239]--[@b34-idr-11-239] The *tlyA* missense mutation observed is an infrequent mutation that is associated with CAP resistance;[@b35-idr-11-239],[@b36-idr-11-239] however, the respective isolates were not tested phenotypically against CAP. There was no mutation in the *eis* gene by both molecular methods. The GenoType MTBDRsl version 2.0 included the *eis* gene probe which was missing in the GenoType MTBDRsl version 1.0 and a study by Tagliani et al showed that the inclusion of the probe for the *eis* promoter gene in the version 2.0 had increased the sensitivity for the detection of resistance to the aminoglycosides. However, this study did not detect any mutation band or missing wild-type band in the *eis* promoter region.[@b37-idr-11-239]

Our analysis, to the best of our knowledge, identified one XDR-TB isolate for the first time in Ghana. The progressive identification of resistant isolates in Ghana if not controlled will pose a great challenge to the control of TB in Ghana. This calls for immediate action, including continuous surveillance, patient counseling/support to improve adherence to treatment and drug supply management to prevent the spread of XDR-TB in Ghana. The findings have been reported to the NTP to take the necessary actions. The contacts of the presumed XDR-TB patient have been screened for TB and are being monitored.

Conclusion
==========

We thus recommend the inclusion of routine testing for second-line drug resistance among RIF and MDR-TB cases in our diagnostic algorithm.

We thank Dr Frank Bonsu, the Director of the NTP Ghana and Department of Chest Diseases, Korle-Bu Teaching Hospital, Ghana, for his support during this study. This study was funded by Wellcome Trust (Grant Number: 097134/Z/11/Z). Stephen Osei-Wusu, a graduate student, was supported by the Holger Pöhlmann Foundation and the West Africa Centre for Cell Biology of Infectious Pathogens (WACCBIP; ACE02-WACCBIP: Awandare), University of Ghana. The funders had no role in the study design, data collection and interpretation, or the decision to submit the work for publication.

**Disclosure**

The authors report no conflicts of interest in this work.

###### 

Primer sequences with the optimized annealing temperature for the targets

  ----------------------------------------------------------------------------------------------------------------
  Gene            Primer name                    Primer sequence                Annealing\         Amplicon size
                                                                                Temperature (°C)   
  --------------- ------------------------------ ------------------------------ ------------------ ---------------
  *gyrA*          F-gyr A                        5′-CAGCTACATCGACTATGCGA-3′     60                 320

  R-gyr A         5′-GGGCTTCGGTGTACCTCAT-3′                                                        

  *gyrB*          F-gyr B                        5′-CGTAAGGCACGAGAGTTGGT-3′     60                 300

  R-gyr A         5′-ATCTTGTGGTAGCGCAGCTT-3′                                                       

  *rrs*           F-rrs                          5′-TTCTAAATACCTTTGGCTCCCT-3′   60                 1,680

  R-rrs           5′-TGGCCAACTTTGTTGTCATGCA-3′                                                     

  *eis*           F-Rv2417c                      5′-GCGGTGCATCACGTCGCCGA-3′     61                 1,660

  R-eis-Rv2415c   5′-GCAACGCGATCCGCGAGTGC-3′                                                       

  *tlyA*          F-tlyA                         5′-GTGGCACGACGTGCCCGCGT-3′     64                 807

  R-tlyA          5′-CTACGGGCCCTCGCTAATCG-3′                                                       

  *tap*           F-Rv1259                       5′-CAGGCCGGCCCTATGCAGTG-3′     61                 1,847

  R-Rv1257c       5′-CGGTCTTGCCGGTAGCCGTC-3′                                                       

  *whiB7*         F URT-whiB7                    5′-GCTGGTTCGCGGTCGGACCT-3′     60                 550

  R whiB7         5′-CGGGGTATCGGCGAACCACA-3′                                                       
  ----------------------------------------------------------------------------------------------------------------

**Abbreviations:** F, forward; R, reverse.

###### 

Characteristics of study participants

  Variable (number of patients)                       Number (%)
  --------------------------------------------------- ------------
  Age (108)                                           
   Average age                                        37 years
   Minimum age                                        13 years
   Maximum age                                        79 years
   Median age                                         34 years
  Gender available (111)                              
   Male                                               83 (74.8)
   Female                                             28 (25.2)
  Patient category (117)                              
   New cases                                          69 (59.0)
   Treatment failure                                  47 (40.2)
   Relapse                                            1 (0.8)
  Location (region) of patients (117)                 
   Greater Accra                                      72 (61.5)
   Central                                            21 (17.9)
   Northern                                           9 (7.7)
   Volta                                              7 (6.0)
   Upper East                                         4 (3.4)
   Brong/Ahafo                                        2 (1.7)
   Western                                            1 (0.9)
   Eastern                                            1 (0.9)
  Year of isolation of isolates from patients (117)   
   2008                                               14 (12.0)
   2010                                               16 (13.7)
   2012                                               10 (8.5)
   2013                                               14 (12.0)
   2014                                               37 (31.6)
   2015                                               26 (22.2)

###### 

Drug resistance profile using Etest, GenoType MTBDRsl and target gene sequencing

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Anti-TB agent   Etest        GenoType MTBDR*sl*   Target gene sequencing                                                                                                    
  --------------- ------------ -------------------- ------------------------ --------- ------------ ----------- --------- ----------------- ------------ -------------------- ----
  **MOX**         115 (99.1)   \<0.094              1 (0.9)                  3         *gyrA*       91 (98.9)   1 (1.1)   FLQ               *gyrA*       G263T (G88C)         1

  **AMK**         104 (89.7)   \<0.75               12 (10.3)                1--16     *rrs*        89 (96.7)   1 (1.1)   AMK/KAN/CAP       *Rrs*\       A1401G + A514C\      2\
                                                                                                                                            *tlyA*       T708G (N236K)        1

  **STR**         79 (68.1)    \<1.5                37 (31.9)                2--1024                                                                                          

  **AMK+MOX**     104 (88.9)   \<0.094              1 (0.9)                  3         *rrs+gyrA*   91 (98.9)   1 (1.1)   AMK/KAN/CAP/FLQ   *rrs+gyrA*   A1401G+A514C+G263T   1
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** MOX, moxifloxacin; AMK, amikacin; STR, streptomycin; MIC, minimum inhibitory concentration; FLQ, fluoroquinolones; KAN, kanamycin; CAP, capreomycin; SNP, single nucleotide polymorphism.

###### 

Correlation between the Etest, Genotype MTBDRsl and target gene sequencing

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
          First-line TB drug susceptibility testing   Second-line TB drug susceptibility testing                                                                                                                                           
  ------- ------------------------------------------- -------------------------------------------- -------- --- --- -------- --------------------------------------------------- --- --------------- ------ --- ------------- --- --- ---- --------------------------------------------------
  1104    R                                           R                                            MDR-TB   R   R   MDR-TB   R(1.25)[a](#tfn3-idr-11-239){ref-type="table-fn"}   S   \_              S      S   \_            S   S   NC   \_

  1216    R                                           R                                            MDR-TB   R   R   MDR-TB   R(8)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   NC   \_

  1273    R                                           R                                            MDR-TB   R   R   MDR-TB   R(1)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   NC   \_

  507     R                                           R                                            MDR-TB   R   R   MDR-TB   R(4)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   NC   \_

  919     R                                           R                                            MDR-TB   R   R   MDR-TB   R(16)[a](#tfn3-idr-11-239){ref-type="table-fn"}     R   *rrs* A1401G\   R(3)   R   *gyrA* G88C   R   R   TF   XDR-TB[b](#tfn4-idr-11-239){ref-type="table-fn"}
                                                                                                                                                                                     *rrs* A514C                                           

  922     R                                           R                                            MDR-TB   R   R   MDR-TB   R(1.5)[a](#tfn3-idr-11-239){ref-type="table-fn"}    S   \_              S      S   \_            S   S   TF   \_

  930     R                                           R                                            MDR-TB   R   R   MDR-TB   R(1)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   TF   \_

  C/050   R                                           R                                            MDR-TB   R   R   MDR-TB   R(3)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   TF   \_

  1542    R                                           S                                            R-R TB   R   S   R-R TB   R(4)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   NC   \_

  1777    R                                           S                                            R-R TB   R   S   R-R TB   R(1.5)[a](#tfn3-idr-11-239){ref-type="table-fn"}    S   \_              S      S   \_            S   S   NC   \_

  93      S                                           R                                            I-R TB   S   R   I-R TB   R(6)[a](#tfn3-idr-11-239){ref-type="table-fn"}      S   \_              S      S   \_            S   S   NC   \_

  16      S                                           R                                            I-R TB   S   R   I-R TB   R(1.5)[a](#tfn3-idr-11-239){ref-type="table-fn"}    S   \_              S      S   \_            S   S   NC   \_
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Not confirmed;

confirmed as XDR-TB.

**Abbreviations:** R, resistant; S, susceptible; R-R TB, rifampicin monoresistant TB; I-R TB, isoniazid monoresistant TB; MDR-TB, multidrug resistant TB; NC, new TB case; TF, treatment failure; NMIMR, Noguchi Memorial Institute for Medical Research; MRCG, Medical Research Council Unit The Gambia; MOX, moxifloxacin; AMK, amikacin; FLQ, fluoroquinolones; KAN, kanamycin; CAP, capreomycin;; XDR-TB, extensively drug-resistant TB; TB, tuberculosis.
